Jessica J Lin1, Adam J Schoenfeld2, Viola W Zhu3, Beow Y Yeap1, Emily Chin1, Marguerite Rooney1, Andrew J Plodkowski4, Subba R Digumarthy5, Ibiayi Dagogo-Jack1, Justin F Gainor1, Sai-Hong Ignatius Ou3, Gregory J Riely2, Alice T Shaw6. 1. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 2. Departments of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. 4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Radiology, Massachusetts General Hospital, Boston, MA. 6. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ashaw1@partners.org.
Abstract
INTRODUCTION: The current standard initial therapy for advanced ALK receptor tyrosine kinase (ALK)-positive NSCLC is a second-generation ALK tyrosine kinase inhibitor (TKI) such as alectinib. The optimal next-line therapy after failure of a second-generation ALK TKI remains to be established; however, standard options include the third-generation ALK TKI lorlatinib or platinum/pemetrexed-based chemotherapy. The efficacy of platinum/pemetrexed-based chemotherapy has not been evaluated in cases that are refractory to second-generation TKIs. METHODS: This was a retrospective study performed at three institutions. Patients were eligible if they had advanced ALK-positive NSCLC refractory to one or more second-generation ALK TKI(s) and had received platinum/pemetrexed-based chemotherapy. RESULTS: Among 58 patients eligible for this study, 37 had scans evaluable for response with measurable disease at baseline. The confirmed objective response rate to platinum/pemetrexed-based chemotherapy was 29.7% (11 of 37 patients; 95% confidence interval [CI]: 15.9% - 47.0%), with median duration of response of 6.4 months (95% CI: 1.6 months - not reached). The median progression-free survival for the entire cohort was 4.3 months (95% CI: 2.9 - 5.8 months). Progression-free survival was longer in patients who received platinum/pemetrexed in combination with an ALK TKI compared to those who received platinum/pemetrexed alone (6.8 months vs. 3.2 months, respectively; hazard ratio = 0.33; p = 0.025). CONCLUSIONS: Platinum/pemetrexed-based chemotherapy shows modest efficacy in ALK-positive NSCLC after failure of second-generation ALK TKIs. The activity may be higher if administered with an ALK TKI, suggesting a potential role for continued ALK inhibition.
INTRODUCTION: The current standard initial therapy for advanced ALK receptor tyrosine kinase (ALK)-positive NSCLC is a second-generation ALK tyrosine kinase inhibitor (TKI) such as alectinib. The optimal next-line therapy after failure of a second-generation ALK TKI remains to be established; however, standard options include the third-generation ALK TKI lorlatinib or platinum/pemetrexed-based chemotherapy. The efficacy of platinum/pemetrexed-based chemotherapy has not been evaluated in cases that are refractory to second-generation TKIs. METHODS: This was a retrospective study performed at three institutions. Patients were eligible if they had advanced ALK-positive NSCLC refractory to one or more second-generation ALK TKI(s) and had received platinum/pemetrexed-based chemotherapy. RESULTS: Among 58 patients eligible for this study, 37 had scans evaluable for response with measurable disease at baseline. The confirmed objective response rate to platinum/pemetrexed-based chemotherapy was 29.7% (11 of 37 patients; 95% confidence interval [CI]: 15.9% - 47.0%), with median duration of response of 6.4 months (95% CI: 1.6 months - not reached). The median progression-free survival for the entire cohort was 4.3 months (95% CI: 2.9 - 5.8 months). Progression-free survival was longer in patients who received platinum/pemetrexed in combination with an ALK TKI compared to those who received platinum/pemetrexed alone (6.8 months vs. 3.2 months, respectively; hazard ratio = 0.33; p = 0.025). CONCLUSIONS:Platinum/pemetrexed-based chemotherapy shows modest efficacy in ALK-positive NSCLC after failure of second-generation ALK TKIs. The activity may be higher if administered with an ALK TKI, suggesting a potential role for continued ALK inhibition.
Authors: Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok Journal: N Engl J Med Date: 2017-06-06 Impact factor: 91.245
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Jessica J Lin; Viola W Zhu; Adam J Schoenfeld; Beow Y Yeap; Ashish Saxena; Lorin A Ferris; Ibiayi Dagogo-Jack; Anna F Farago; Angela Taber; Anne Traynor; Smitha Menon; Justin F Gainor; Jochen K Lennerz; Andrew J Plodkowski; Subba R Digumarthy; Sai-Hong Ignatius Ou; Alice T Shaw; Gregory J Riely Journal: J Thorac Oncol Date: 2018-06-20 Impact factor: 15.609
Authors: Alice T Shaw; Benjamin J Solomon; Benjamin Besse; Todd M Bauer; Chia-Chi Lin; Ross A Soo; Gregory J Riely; Sai-Hong Ignatius Ou; Jill S Clancy; Sherry Li; Antonello Abbattista; Holger Thurm; Miyako Satouchi; D Ross Camidge; Steven Kao; Rita Chiari; Shirish M Gadgeel; Enriqueta Felip; Jean-François Martini Journal: J Clin Oncol Date: 2019-03-20 Impact factor: 44.544
Authors: Malinda Itchins; Brandon Lau; Amanda L Hudson; Helen Westman; Cathy Yi Xia; Sarah A Hayes; Viive M Howell; Michael Rodriguez; Wendy A Cooper; Heng Wei; Michael Buckland; Bob T Li; Mark Li; Vivek Rathi; Stephen B Fox; Anthony J Gill; Stephen J Clarke; Michael J Boyer; Nick Pavlakis Journal: Oncologist Date: 2020-07-02
Authors: Alessandro Russo; Andrés F Cardona; Christian Caglevic; Paolo Manca; Alejandro Ruiz-Patiño; Oscar Arrieta; Christian Rolfo Journal: Transl Lung Cancer Res Date: 2020-12